High Telomerase Activity Correlates with the Stabilities of Genome and DNA Ploidy in Renal Cell Carcinoma  by Izumi, Hideki et al.
High Telomerase Activity Correlates with the Stabilities of
Genome and DNA Ploidy in Renal Cell Carcinoma1
Hideki Izumi*,2,3, Takahiko Hara y,2, Atsunori Oga*, Kenji Matsuda y, Yuko Sato z, Katsusuke Naito y
and Kohsuke Sasaki*
Departments of *Pathology, yUrology, Yamaguchi University School of Medicine, 1-1-1, Minami Kogushi,
Ube-city, Yamaguchi, 755-8505, Japan; zDivision of Molecular Cytogenetics, Department of Clinical Pathology,
Research Institute, International Medical Center of Japan (IMCJ), 1-12-1, Toyama, Shinjyuku-ku, Tokyo,
162-0052, Japan
Abstract
Malignant tumors have telomerase activity, which is
thought to play a critical role in tumor growth. However,
the relation between telomerase activity and genomic
DNA status in tumor cells is poorly understood. In the
present study, we examined telomerase activity in 13
clear cell type renal cell carcinomas (CRCCs) with
similar clinicopathologic features by telomeric repeat
amplification protocol assay (TRAP). Based on TRAP
assay results, we divided the CRCCs into two groups: a
high telomerase activity group and a low/no telomer-
ase activity group. We then analyzed genomic aberra-
tion, DNA ploidy, and telomere status in these two
groups by comparative genomic hybridization (CGH),
laser scanning cytometry (LSC), and telomere-specific
fluorescence in situ hybridization (T-FISH), respec-
tively. CGH showed the high telomerase activity group
to have fewer genomic changes than the low/no
telomerase activity group, which had many genomic
aberrations. Moreover, with LSC, DNA diploid cells
were found more frequently in the high telomerase
activity group than in the low/no telomerase activity
group. In addition, T-FISH revealed strong telomere
signal intensity in the high telomerase activity group
compared with that of the low/no telomerase activity
group. These results suggest that telomerase activity is
linked to genomic DNA status and that high telomerase
activity is associated with genomic stability, DNA
ploidy, and telomere length in CRCC.
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Introduction
Telomerase is the essential enzyme that maintains the very
end of the chromosome, the telomere, and the enzyme is
thought to be involved in proliferating potential and immor-
talized growth of tumor cells [1,2 ] . Cells that lack telomerase
activity gradually lose the telomere repeat sequence (50 -
TTAGGG-30 ) with increasing numbers of cell divisions.
When telomere length in chromosomes is severely reduced,
cells are confronted with a growth crisis or accelerated aging.
Such cells also show frequent structural aberrations in
chromosomes such as dicentricity, and show DNA aneu-
ploidy [3,4 ] . This suggests that telomeres prevent individual
chromosomes from fusing and breaking and, in turn,
telomerase stabilizes the overall genomic DNA structure by
maintaining the telomere [3,5 ] . Normal adult somatic cells,
except germ cells, blood cells, and stem cells, do not possess
telomerase activity, but many types of malignant cells show
reactivation of telomerase activity [1,2,6,7] . However, it is
unclear whether telomerase contributes to genomic stability
in tumor cells.
Human telomerase is composed of an RNA subunit
(hTR), a catalytic subunit (hTERT) , and telomerase-
associated protein (TEP1) [8] . The hTR gene is expressed
ubiquitously in various normal tissues, and hTERT gene
expression is activated in many tumors and appears to be
involved in immortalized growth of tumor cells [9,10] .
Telomerase activity is expressed in approximately 60% to
92% of renal cell carcinoma (RCC) cases [11–16] .
However, telomerase activity showed wide variability even
between cases with similar clinicopathologic characteristics
[13,16] . In addition, the relation between telomerase activity
and genomic DNA status has not been clarified in many
tumors, including RCC. Therefore, as a pilot study, we
investigated this relation in specimens of RCC tissue with
identical histologic cell types, nuclear grades, and similar
TNM stages. Our results suggest that genomic DNA status
is associated with telomerase activity and that high
telomerase activity is correlated with genomic stability in
CRCC.
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BRIEF ARTICLE
Materials and Methods
Tissue Specimens and Microdissection
We obtained tissue specimens from surgically resected
tumors in 13 similar cases of CRCC (Table 1) . The patients,
9 men and 4 women with a mean age of 56 years (range 36
to 84) were all treated at Yamaguchi University Hospital.
Tumor TNM stages were determined according to the UICC
criteria (1992) , and the nuclear grades were determined
according to the Skinner grading system [17] . Family
histories were noncontributory in all cases. The tumor
samples and adjacent normal samples were frozen in liquid
nitrogen as quickly as possible after excision, and stored at
808C until use. Thirteen frozen tumor specimens were
microdissected by one pathologist (A.O.) as reported
previously [18] . Briefly, we prepared 60 to 80 pieces of
30-m frozen tissue sections from each sample and stained
them with hematoxylin and eosin for identifying cancerous
regions in the tissue section. Cancerous regions were
manually isolated from surrounding nontumor areas by
microdissection with a 26-gauge hypodermic needle and
syringe, and then transferred into microtubes.
Measurement of Telomerase Activity by Telomeric Repeat
Amplification Protocol (TRAP) Assay
We analyzed telomerase activity by modified TRAP assay
to avoid endogenous PCR inhibitor (s) in the 13 selected
cases of CRCC. We followed a previously reported method
[19] but with some modifications, also previously reported
[16] . Briefly, the assay was performed in a 40-l reac-
tion mixture containing 20 mM Tris–HCl (pH 8.0) , 1 mM
dNTPs, 2.5 Ci of [ -32P] dCTP (3000 Ci /mmol) , 1 mM
MgCl2, 2 mM ethylene glycol -bis ( -aminoethyl ether ) -
N,N,N 0,N 0 - tetraacetic acid, 100 g/ml BSA, 10 pmol TS
primer (50 -AAT CCG TCG AGC AGA GTT-30 ) and 2- or
20-g aliquots of proteins from T24 cell extracts (control ) or
tissue samples. Each mixture was incubated at 308C for 60
minutes to achieve telomerase-mediated extension of TS
primer, then heated at 958C for 10 minutes, and the DNAwas
precipitated with two volumes of ethanol. To amplify the
precipitated DNA, 10 pmol ACX primer (50 -GCG CGG CTT
ACCCTT ACCCTT ACCCTA ACC-30 ) , 10 pmol NT primer
(50 -ATC GCT TCT CGG CCT TTT-30 ) , and 20 pmol PCR
control template (50 -AAT CCG TCG AGC AGA GTT AAA
AGG CCG AGA AGC GAT-30 ) were added. The reaction
mixture was incubated at 308C for 60 minutes and then
subjected to 31 PCR cycles each comprising 948C for 30 s,
558C for 30 s, and 728C for 45 s. The PCR product was
electrophoresed on a 10% polyacrylamide gel. To quantify
telomerase activity, we analyzed the signal intensity of TRAP
assay–generated DNA ladder using the Bioimage analyzer
(BAS 2000; Fuji, Tokyo, Japan) .
DNA Extraction
Genomic DNA was extracted from tissue fragments for
comparative genomic hybridization (CGH) analysis as
reported previously [18] . Briefly, genomic DNA was
obtained from microdissected tissue fragments and from
lymphocytes ( for reference DNA) with a DNA extraction kit
(SepaGene, Sanko Junyaku, Tokyo, Japan) according to
themanufacturer’s instructions. DNA was suspended in 17 l
of 10 mM Tris–HCl EDTA solution, and DNA concentration
was measured.
Table 1. Cases of 13 CRCCs Examined.*
Case Patient Age (yr ) /Sex Telomerase Activityy TNM Staging
1 41 /F None pT2NOMO
2 36 /F Low pT2NOMO
3 60 /M Low pT3aNOM1
4 46 /M Low pT2NOMO
5 42 /M Low pT2NOMO
6 75 /M Low pT2NOMO
7 84 /M Low pT2NOMO
8 68 /M High pT3aNOMO
9 74 /M High pT2NOMO
10 43 /F High pT2NOMO
11 40 /M High pT2NOMO
12 77 /F High pT2NOMO
13 45 /M High pT3aN3MO
*All are nuclear grade G2.
yThe telomerase activity levels in each sample were normalized according to
level in the T24 cell line ( control, 100%) . High, relative ratio greater than
20%. Low, relative ratio less than 20%. None, no activity.
Figure 1. Distribution of relative telomerase activity in 13 CRCCs. Telomerase
activity of the T24 bladder carcinoma cell line was used as a positive control
( 100%) and the relative telomerase activity of each tumor sample was
plotted. Based on the mean of the relative telomerase activities for all the
samples, we defined 20% as the standard level ( bar ) and divided the samples
into two groups: a high telomerase activity group ( ; n=6 ) and a low /no
telomerase activity group (6; n=7 ) .
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Comparative Genomic Hybridization (CGH) and Digital
Image Analysis
CGH analysis including digital image analysis was
performed as described elsewhere [18,20] . Briefly, DNA
extracts from tumor cells and lymphocytes were labeled with
Spectrum Green-dUTP and Spectrum Red-dUTP (Vysis,
Downers Grove, IL) , respectively, by nick translation.
Labeled DNA samples (200 ng) and Cot-1 DNA (10 mg)
were dissolved in 10 l of hybridization buffer and cohybri-
dized to normal denatured metaphase chromosomes for
72 hours at 378C. The specimens were mounted in antifade
solution containing 0.15 ng/ml 40,60 -diamino-2-phenylin-
dole (DAPI) as a counterstain. Images were captured with
an Olympus BX50 epifluorescence microscope equipped
with a 100 UplanApo objective (Olympus, Tokyo, Japan)
and a CCD camera (Sensys1400, Photometrics, Tucson,
AZ). A digital image analysis system (QUIPS XL, Vysis)
was used in this experiment. At least 6, usually 10,
representative images were analyzed, and the results were
combined to produce an average fluorescence ratio for each
chromosome. Increases (gains) and decreases ( losses) in
DNA copy numbers were defined by green- to- red ratios of
1.2 and 0.8, respectively. High- level copy number increases
in subregions (amplifications) were defined by a tumor- to-
reference ratio of 1.4.
Measurement of Nuclear DNA by Laser Scanning
Cytometry (LSC)
The procedure was as described previously [18] .
Briefly, tumor touch smear slides were prepared, fixed in
70% ethanol, and dipped in propidium iodide solution
(25 mg/ml in phosphate-buffered saline) containing 0.1%
RNase (Sigma, St. Louis, MO). Slides were coverslipped
and sealed with nail polish. Nuclear DNA content was
measured with a laser scanning cytometer (LSC 101,
Olympus) . A histogram was generated, and DNA ploidy
was determined.
Telomere-Specific Fluorescence In Situ Hybridization
(T-FISH)
Human telomeric DNA probe hybridization kit was
purchased from Dako (AS Glostrup, Denmark) . The
experimental procedure was according to the manufactur-
er’s instruction. Briefly, tumor touch smear slides were
prepared, and the slides were immersed in Tris -buffered
saline (TBS) for 2 minutes and immersed in 3.7%
formaldehyde in TBS for 2 minutes. Next, the slides were
washed twice in TBS for 5 minutes. The fixed slides were
immersed in pretreatment solution for 10 minutes, washed
twice in TBS for 5 minutes, dehydrated in 70%, 85%, and
96% ethanol, respectively, for 2 minutes each, and air dried.
Ten microliters of fluorescein-labeled telomere PNA probe
[FITC(CCCTAA)3] was added to the slide. The slides were
coverslipped, heated for 3 minutes at 808C and placed in the
dark room at room temperature for 60 minutes. The slides
were immersed in preheated wash solution for 5 minutes at
658C, dehydrated in 70%, 85%, and 96% ethanol, respec-
tively, for 2 minutes each and air dried. Next, the slides
were counterstained with DAPI containing antifade (Vysis) .
Fluorescence images of tumor cell nuclei and adjacent
Figure 2. Summary of CGH analyses of 13 CRCCs. Lines to the left of chromosomes represent losses (CGH fluorescence ratios less than 0.8; red ) ; lines to the
right of chromosomes represent gains ( ratios greater than 1.2; green ) . Solid lines represent high telomerase activity cases, hatched lines indicate low telomerase
activity cases, and bleached lines are no telomerase activity cases.
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normal cell nuclei were captured with epifluorescence
microscope (BX50, Olympus) equipped with a plan
apochromatic objective (UplanApo 100, Olympus) and
a CCD camera (SenSys 1400, Photometrics) . In each
tumor, we also examined T-FISH in normal adjacent tissue,
which was located far from cancerous tissue. In addition,
when the T-FISH was performed, one pathologist (A.O.)
checked the cytologic appearance of cells one by one, as
we reported previously [21] .
Signal intensities of 20 nuclei of tumor cells and of
normal cells in each tissue were measured on a pixel -by-
pixel basis by digital image analysis system (QUIPS XL,
Vysis) .
Statistical Analysis
On the basis of telomerase activity status of CRCCs,
differences in the average chromosomal aberration number,
DNA ploidy status, and telomere signal intensity of CRCCs
were examined by Mann-Whitney U test. Statistical analysis
was performed using a statistical software package (Stat-




We previously determined the telomerase activity of 23
cases of RCC [16] . The data demonstrated that telomerase
activity status varied between the samples with similar
clinicopathologic features. Because of this variability, we
chose to explore the relation between telomerase activity and
genomic aberration in samples with similar clinicopathologic
characteristics and we, thus, selected 13 specimens of
identical cell type, identical nuclear grade, and similar TNM
stage from the available samples (Table 1) . In this study, to
avoid endogenous PCR inhibitor (s) , a modified TRAP assay
was performed as described previously [16] . As shown in
Figure 1, when telomerase activity of the T24 bladder cancer
cell line was used as the positive control (100%), the
distribution of the relative telomerase activity was broad (0%
to 66.0%) even though the specimens were similar
clinicopathologically. In the present study, 12 cases had
measurable telomerase activity, and one case showed no
telomerase activity. The mean relative telomerase activity
was 20.7%. To evaluate the relation between telomerase





Losez Gainx DNA Ploidy
(DNA Index ){
Normal# None 0 DD (1.0 )
1 None 11 3p 22 -pter 8p 22 -pter
10q25 -qter 14q22 -qter
17 p13 19p 13
2q32 6q22 -24 12q 12 -13.1
20p 13 Xp 11.2 - q12
DA (1.66 )
2 Low 9 3p 26 8p 22 10p 15.1
21q11.2 -qter Xp 22.3
3q21 5q31 33 12q15 17p 13 DA (1.62 )
3 Low 7 3p 12 -p ter 8p 23 1q21 -qter 5q23 -qter 20p 13 Xp Xq DA (1.56 )
4 Low 8 3p 13 -pter 14q 12 -qter 2p 11 -pter 2q 11 -qter 12q 12 -13.1
20p 13 Xp Xq
DD (1.0 )
5 Low 9 3p 25 -pter 8p 23 10q26 3q 13 -qter 8q24 12p 11 -pter
12q 12 -qter 20p 13 Xq 13
DA (1.25 )
6 Low 8 2q36 -qter 3p 12 -pter
8p23 22q13
5q 15 -22 7p 11 -pter 7q11 -qter
Xq 12 -13
DA (1.54 )
7 Low 7 3p 21.3 -pter 10q26
15q11.2 -qter 21q11.2 - qter
1a21.2 - qter 2p 11.2 -pter 2q 12 -qter DD (1.0 )
8 High 4 3p 25 -pter 8p 22 -23 10a26 20p 13 DD (1.0 )
9 High 4 3p 25 -pter 12q24.31 -qter 5q31 -qter Xq21.3 - 22.2 DD (1.0 )
10 High 4 3p 14.1 -pter 8q34 5q11.1 - qter 20p 13 DD (1.0 )
11 High 5 3p22 -pter 8p23 8q23 -qter 5q11.1 - qter Xq13 DA (1.42 )
12 High 1 3p21.3 -pter DD (1.0 )
13 High 6 3p21.3 -pter 4g35 5p 15.3 12g 12 -13.1
18p 11.3 20p 13
DD (1.0 )
*Telomerase activity is described in Table 1.
yAberration number is number of region with DNA copy number abberations detected by CGH.
zLoss means underpresentation detected by CGH, and such aberrant chromosomal regions are shown.
xGain means overpresentation detected by CGH, and such aberrant chromosomal regions are shown.
{DNA ploidy was measured by LSC. DD: DNA diploidy, DA: DNA aneuploidy.
#Normal is adjacent normal tissue of case 1.
Figure 3. Representative results of CGH in CRCCs with different telomerase activities. (A ) , (D ) , and (G ) show CGH images of high telomerase activity, low
telomerase activity, and no telomerase activity tumors, respectively. (B ) , (E ) , and (H ) show the results of TRAP assays in high telomerase (high ) , low
telomerase ( low ) , and no telomerase (no ) tumors, respectively. The results of a TRAP assay of the T24 bladder carcinoma cell line was used as a positive control
(T24 ) . (C ) , (F ) , and ( I ) show the CGH profiles of high telomerase activity, low telomerase activity, and no telomerase activity tumors, respectively. High
telomerase activity tumors showed greater genomic stability compared to the low /no telomerase activity tumors. (A ) , (B ) , and (C ) are data from case 11; (D ) ,
(E ) , and (F ) are data from case 6; and (G ) , (H ) , and ( I ) are data from case 1.
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activity and genomic DNA status, we divided these 13 cases
into two groups. On the basis of themean relative telomerase
activity, we defined 20% as a standard level and divided the
CRCCs into two groups: a high telomerase activity ( >20%)
group (n=6) and a low/no telomerase activity ( <20%)
group (n=7) . With respect to variance, these two groups
were statistically equal, and there was no significant age
disparity between these two groups (Figure 1, Table 1) .
Relation between Telomerase Activity and Genomic
Aberrations
To explore genetic differences between the two groups,
we analyzed the specimens by CGH. CGH demonstrated
DNA copy number aberration(s) in all cases, but there were
no amplifications. The results are summarized in Figure 2.
CGH showed a consistent loss of chromosome 3p (13/13,
100%). In addition, high frequency ( >50%) of loss of
chromosome 8p (7/13, 54%) and gains of 5q (7/13, 54%),
20p (7/13, 54%), and X (7/13, 54%) were revealed. These
common aberrations were found to be independent of
telomerase activity (Table 1) , in contrast to previously
reported findings for other tumors [22,23] . However, the
high telomerase activity group showed few changes in
addition to the frequent changes described above, whereas
the low/no telomerase activity group showed many addi-
tional alterations (P<0.0025) (Table 2, Figure 4A ) .
Representative data are shown in Figure 3. From these
results, it appears that the frequency of genomic aberrations
was inversely correlated with telomerase activity, with high
telomerase activity being associated with a low frequency of
DNA copy number aberrations in our CRCCs, possibly due to
increased genomic stability.
Relation between Telomerase Activity and Both DNA Ploidy
and Telomere Status
To elucidate whether telomerase activity was also related
to nuclear DNA ploidy, we analyzed nuclear DNA ploidy
status by LSC. The LSC analyses revealed most cases in the
high telomerase activity group to be DNA diploid (5/6,
83%); the majority of low/no telomerase cases were DNA
aneuploid (5/7, 71%) (P<0.05) (Table 2, Figure 4B ) .
Finally, we performed T-FISH to investigate whether
telomerase activity influenced telomere status (Figure 5 ) .
Representative T-FISH images are shown in Figure
5A and B. Quantitative analyses of T-FISH data revealed
that the mean signal intensity of the high telomerase activity
group was approximately 1.5- fold higher than that of the
low/no telomerase activity group (Figure 5C ) . These
findings indicate that the high telomerase activity group
had longer telomeres than the low/no telomerase activity
group. We also analyzed the telomere signal intensities of
adjacent normal cells. The analyses showed that the
Figure 4. Relation between telomerase activity, chromosome aberrations, and DNA ploidy. (A ) Frequency of DNA copy number aberrations detected by CGH in the
low or no telomerase activity tumors ( low /no ) and the high telomerase activity tumors (high ) . High telomerase activity tumors had fewer genome aberrations than
low /no telomerase activity tumors (P<0.0025 by *Mann -Whitney U test ) . (B ) Frequency of DNA diploidy detected by LSC in low or no telomerase activity tumors
( low / no ) and high telomerase activity tumors (high ) . High telomerase activity tumors were DNA diploid more frequently than were low / no telomerase activity
tumors (P<0.05 by *Mann -Whitney U test ) .
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telomere signal intensity of normal cells tended to weaker
with age; however, signal intensity was not statistically
different between normal cells from the two telomerase
activity groups (Figure 5C ) . These results suggest that high
telomerase activity stabilizes the telomeres of chromosomes
in tumor cells.
Taking the results of the present study together, we
conclude that telomerase activity is linked to genomic DNA
status and that high telomerase activity is associated with
genomic stability, DNA ploidy, and telomere length in CRCC.
Discussion
In the present study, we examined the relation between
telomerase activity and genomic DNA status in a limited
number of cases of CRCC. Telomerase activity varied widely
when CRCCs with similar clinicopathologic features were
compared. To clarify this association, we examined 13 cases
of CRCC with similar clinicopathologic features. In the
present study, we divided the CRCCs into two groups, a
high telomerase activity group and a low/no telomerase
activity group on the basis of mean relative telomerase
activity. Our analyses reveal a suggestive relation between
telomerase activity and genomic DNA status in CRCCs.
CGH analyses revealed consistent loss of chromosome
3p, which harbors the VHL tumor suppressor gene at 3p25–
26 [24] . Inactivation of the VHL gene is considered an early
step in clear cell type renal cell carcinogenesis [25] . The
frequency of 3p loss in CRCC as assessed by CGH has been
reported as approximately 60% [26,27] , whereas the
frequency of 3p loss from LOH analyses was reported to
be approximately 90% [28] . The high frequency of 3p loss in
the present study is likely due to the method of tissue
sampling for DNA extraction. We isolated cancerous tissues
from each resection sample by microdissection, a technique
known to yield high resolution for CGH analysis [18] . Loss of
8p and gains of 5q and 20p were also observed frequently as
reported previously [29,30] . In the present study, we found
that these genetic aberrations might be involved in clear cell
type renal cell carcinogenesis, but they were independent of
telomerase activity. There was a discrepancy between the
numbers of DNA copy number aberrations in our two
telomerase activity groups, suggesting that the frequency
of genomic aberrations is influenced by telomerase activity
status. Cells with high levels of telomerase expression are
known to be genetically stable [31] , and telomerase-
deficient cells or cells expressing low levels of telomerase
show various random structural aberrations of chromosomes
as well as DNA aneuploidy [32,33] . In addition, Artandi et al.
[34] reported that telomere dysfunction resulting from
telomerase deficiency promoted nonreciprocal transloca-
tions and epithelial cancers in mice. In fact, our CGH results
demonstrated that tumors with low or no telomerase
activities had more genomic aberrations than tumors with
high telomerase activity. Thus, low or no telomerase activity
may contribute to telomere dysfunction and result in gross
genomic aberrations [35] . However, in a preliminary study
of various types of RCC (Izumi et al., unpublished data) , we
Figure 5. High telomerase activity group exhibited strong telomere signal intensity compared to that of the low /no telomerase activity group. (A ) Representative
image of a high telomerase activity case ( case 1 ) and (B ) a low telomerase activity case ( case 10 ) . Insets show representative images of telomere signal
intensities of normal cells in each case. Quantitative calculations of telomere signal intensities (A.U.; arbitrary unit on a pixel - by - pixel basis ) are shown in (C ) . The
high telomerase activity group (solid bars ) exhibited strong telomere signal intensity compared to that in the low /no telomerase activity group (gray bars ) (P<0.05
by *Mann -Whitney U test ) . Open bars show telomere signal intensities of adjacent normal cells.
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did not obtain results similar to those of the present study.
Therefore, the findings of the present study are likely
applicable only to a subset of tumors, including CRCC, but
not all tumors.
DNA ploidy status is related to the extent of genome
aberrations as detected by CGH [18,36] . In the present
study, CRCCs with high telomerase activity were DNA
diploid more frequently than were low or no telomerase
activity CRCCs. However, other investigators have reported
no correlation between telomerase activity and DNA ploidy in
RCC [13,37,38] . This discrepancy could be explained by the
types of specimens analyzed. We used specimens from
tumors that were of the same histologic cell type, same
nuclear grade, and similar pathologic stage, whereas other
researchers have used specimens from varying types of
RCCs. Thus, telomerase activity may be related to nuclear
DNA ploidy in CRCC as well as in normal cells and other
tumor cells [32,39] . However, to clarify this point, further
large scale studies are necessary.
In the present study, we also examined telomere status by
T-FISH. This method is useful for obtaining information
regarding telomere status, and the signal intensity with T-
FISH is known to correlate with telomere length [40] . Our
results demonstrate that the high telomerase activity group
has higher mean telomere signal intensity than the low/no
telomerase activity group. Other investigators have reported
that reactivation of telomerase of some cells with genomic
instability stabilizes the genome and DNA ploidy in culture
systems [41,42] . Therefore, it is likely that high telomerase
activity lead to telomere stability, resulting in genomic
stability in clinical tumor specimens.
It is known that some large CRCCs are not necessarily
malignant and that some small CRCCs are very aggressive.
This discrepancy might be explained by telomerase activity
status because CRCCs that have high telomerase activity
during the early stages of tumor development may be
genetically stable and may yield more favorable outcomes
than results from those with low or no telomerase activity
CRCC (Hara et al., unpublished data) . However, it is
possible that CRCCs with high telomerase activity may
develop genomic instability at later stages due to another
mechanism, such as destruction of the mitotic apparatus
[43] . In contrast, CRCCs with low or no telomerase activity
that may not be immortal at an early stage could express
high levels of telomerase activity later, resulting in
stabilization of their gross genomic aberrations that would
permit tumor progression as Rudolph et al. [44] reported
recently.
In conclusion, the sample size in this preliminary study is
very small, and the data are potentially misleading; therefore,
further large-scale studies are necessary. However, to our
knowledge, this is the first report of the relation between
telomerase activity and genomic stability in human primary
tumors, and we believe that our results may provide
important insights into aspects of telomerase activity status
and genomic aberration. Moreover, our data suggest that
high telomerase activity plays an important role in genomic/
chromosomal stability in CRCCs.
Acknowledgements
The authors gratefully thank T. Shimizu and Y. Mukae for
critical reading, A. Shiraki for technical assistance, and the
members of our laboratory for their helpful discussion.
References
[1] Greider CW (1998 ) . Telomerase activity, cell proliferation, and cancer.
Proc Natl Acad Sci USA 95, 90–92.
[2] Artandi SE, and DePinho RA (2000 ) . A critical roles for telomeres in
suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 10,
39–46.
[3] Harley CB, and Sherwood SW (1997 ) . Telomerase, checkpoints and
cancer. Cancer Surv 29, 263–84.
[4] Ducray C, Pommier JP, Martins L, Boussin FD, and Sabatier L ( 1999 ) .
Telomere dynamics, end - to -end fusions and telomerase activation
during the human fibroblast immortalization process. Oncogene 18,
4211–23.
[5] Ishikawa F (1997 ) . Telomere crisis, the driving force in cancer cell
evolution. Biochem Biophys Res Commun 230, 1 –6.
[6] Shay JW, and Wright WE (1996 ) . The reactivation of telomerase
activity in cancer progression. Trends Genet 12, 129–31.
[7] Shay JW, and Bacchetti S ( 1997 ) . A survey of telomerase activity in
human cancer. Eur J Cancer 33, 787–91.
[8] Meyerson M (2000 ) . Role of telomerase in normal and cancer cells.
J Clin Oncol 18, 2626–34.
[9] Hahn WC, Stewart SA, Brooks MW, York SG, Ng Eaton E, Kurachi A,
Beijersbergen RL, Knoll JHM, Meyerson M, and Weinberg RA (1999 ) .
Inhibition of telomerase limits the growth of human cancer cells. Nat
Med 5, 1164–70.
[10] Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg,
RA, Haber DA, and Gerald WL (1998 ) . Expression of TERT in early
premalignant lesions and a subset of cells in normal tissues. Nat Genet
19, 182–86.
[11] Mehle C, Piatyszek MA, Ljungberg B, Shay JW, and Roos G (1996 ) .
Telomerase activity in human renal cell carcinoma. Oncogene 13,
161–66.
[12] Kinoshita H, Ogawa O, Mitsumori K, Kakehi Y, Terachi T, and Yoshida
O ( 1998 ) . Low frequency of positive telomerase activity in a
chromophobe subtype of renal cell carcinoma. J Urol 159, 245–51.
[13] Rohde V, Sattler HP, Oehlenschlager B, Forster S, Zwergel T, Seitz G,
and Wullich B. (1998 ) . Genetic changes and telomerase activity in
human renal cell carcinoma. Clin Cancer Res 4, 197–202.
[14] Dahse R, Fiedler W, Junker K, Schlichter A, Schubert J, and Claussen
U (1999 ) . Telomerase activity and telomere length: alterations in renal
cell carcinomas. Kidney Int 56, 1289–90.
[15] Sugimura K, Yoshida N, Hisatomi H, Nakatani T, and Ikemoto S
(1999 ) . Telomerase activity and telomere length: alterations in renal
cell carcinomas. Br J Urol 83, 693–97.
[16] Hara T, Noma T, Yamashiro Y, Naito K, and Nakazawa A (2001 ) .
Quantitative analysis of telomerase activity and telomerase reverse
transcriptase expression in renal cell carcinoma. Urol Res 29, 1 –6.
[17] Skinner DG, Colvin RB, Vermillion CD, Pfister RC, and Leadbetter WF
(1971 ) . Diagnosis and management of renal cell carcinoma. A clinical
and pathologic study of 309 cases. Cancer 28, 1165–77.
[18] Hashimoto Y, Oga A, Okami K, Imate Y, Yamashita Y, and Sasaki K
( 2000 ) . Relationship between cytogenetic aberrations by CGH
coupled with tissue microdissection and DNA ploidy by laser scanning
cytometry in head and neck squamous cell carcinoma. Cytometry 40,
161–66.
[19] Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC,
Coviello GM, Wright WE, Weinrich SL, and Shay JW (1994 ) . Specific
association of human telomerase activity with immortal cells and
cancer. Science 266, 2011–15.
[20] Harada K, Nishizaki T, Ozaki S, Kubota H, Ito H, and Sasaki K ( 1998 ) .
Intratumoral cytogenetic heterogeneity detected by comparative geno-
mic hybridization and laser scanning cytometry in human gliomas.
Cancer Res 58, 4694–4700.
[21] Miyazaki M, Furuya T, Shiraki A, Sato T, Oga A, and Sasaki K ( 1999 ) .
The relationship of DNA ploidy to chromosomal instability in primary
human colorectal cancers. Cancer Res 59, 5283–85.
[22] Brinksmidt C, Premba C, Christiansen H, Simon R, Schafer KL, Terpe
HJ, Lampert F, Boecker W, and Dockhorn -Dworniczak B (1998 ) .
Comparative genomic hybridization and telomerase activity analysis
110 Telomerase and Genomic Stability in CRCC Izumi et al.
Neoplasia . Vol. 4, No. 2, 2002
identify two biologically different groups of 4s neuroblastomas. Br J
Cancer 77, 2223–29.
[23] Loveday RL, Greeman J, Drew PJ, Monson JRT, and Kerin MJ
(1999 ) . Genetic changes associated with telomerase activity in breast
cancer. Int J Cancer 84, 516–20.
[24] Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse
T, Kuzmin I, Modi W, Gei IL, et al. ( 1993 ) . Identification of the
von Hippel - Lindau disease tumor suppressor gene. Science 260,
1317–20.
[25] Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu F,
Chen F, Duh FM, et al. ( 1994 ) . Mutations of the VHL tumor suppressor
gene in renal carcinoma. Nat Genet 7, 85–90.
[26] Presti JC, Moch H, Reuter VE, Cordon -Cardo C, and Waldman FM
(1996 ) . Renal cell carcinoma genetic analysis by comparative genomic
hybridization and restriction fragment length polymorphism analysis.
J Urol 156, 281–85.
[27] Bissig H, Richter J, Desper R, Meier V, Schraml P, Schaffer AA, Sauter
G, Mihatsch MJ, and Moch H (1999 ) . Evaluation of the clonal
relationship between primary and metastatic renal cell carcinoma by
comparative genomic hybridization. Am J Pathol 155, 267–74.
[28] Anglard P, Brauch TH, Weiss GH, Latif F, Merino MJ, Lerman MI, Zbar
B, and Linehan WH (1991 ) . Molecular analysis of genetic changes in
the origin and development of renal cell carcinoma. Cancer Res 51,
1071–77.
[29] Kovacs G (1993 ) . Molecular cytogenetics of renal cell tumors. Adv
Cancer Res 62, 89–124.
[30] Schullerus D, Knobloch RV, Chudek J, Herbers J, and Kovacs G
(1999 ) . Microsatellite analysis reveals deletion of a large region at
chromosome 8p in conventional renal cell carcinoma. Int J Cancer 80,
22–24.
[31] Morales CP, Holt SE, Ouellete M, Kaur KJ, Yan Y, Wilson KS, White
MA, Wright WE, and Shay JW (1999 ) . Absence of cancer -associated
changes in human fibroblasts immortalized with telomerase. Nat Genet
21, 115–18.
[32] Sherwood SW, Rush D, Ellsworth JL, and Schimke RT (1988 ) .
Defining cellular senescence in IMR -90 cells: a flow cytometric
analysis. Proc Natl Acad Sci USA 85, 9086–90.
[33] Counter CM, Avillon AA, Lefeuve CE, Stewart NG, Greider CW, Harley
CB, and Bacchetti S ( 1992 ) . Telomere shortening associated with
chromosome instability is arrested in immortal cells which express
telomerase activity. EMBO J 11, 1921–29.
[34] Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, and
DePinho RA (2000 ) . Telomere dysfunction promotes non - reciprocal
translocations and epithelial cancers in mice. Nature 406, 641–44.
[35] Artandi SE, and DePinho RA (2000 ) . Mice without telomerase: what
can they teach us about human cancer? Nat Med 6, 852–55.
[36] De Angelis PM, Clausen OPF, Schjolberg A, and Stokke T (1999 ) .
Chromosomal gains and losses in primary colorectal carcinomas
detected by CGH and their associations with tumor DNA ploidy,
genotypes and phenotypes. Br J Cancer 80, 526–35.
[37] Thrash -Binbham CA, Salazar H, Freed JJ, Greenberg RE, and Tartof
KD ( 1995 ) . Genomic alterations and instabilities in renal cell
carcinomas and their relationship to tumor pathology. Cancer Res 55,
6189–95.
[38] Wada Y, Igawa M, Shiina H, Shigeno K, Yokogi H, Urakami S, Yoneda
T, and Maruyama R (1998 ) . Comparison of chromosomal aberrations
detected by fluorescence in situ hybridization with clinical parameters,
DNA ploidy and Ki67 expression in renal cell carcinoma. Br J Cancer
77, 2003–2007.
[39] Koeneman KS, Pan CX, Jin JK, Pyle JM III, Franigan RC, Shankey
V, and Diaz MO (1998 ) . Telomerase activity, telomere length, and
DNA ploidy in prostatic intraepithelial neoplasia (PIN ) . J Urol 160,
1533–39.
[40] Lansdorp PM, Verwoerd NP, van de Rijke FM, Dragowska V, Little MT,
Dirks RW, Raap AK, and Tanke HJ (1996 ) . Heterogeneity in telomere
length of human chromosomes. Hum Mol Genet 5, 685–91.
[41] Henderson S, Allsopp R, Spector D, Wang SS, and Harley C (1996 ) .
In situ analysis of changes in telomere size during replicative aging and
cell transformation. J Cell Biol 134, 1 –12.
[42] Golubovskaya VM, Filatov LV, Behe CI, Presnell SC, Hooth MJ, Smith
GJ, and Kaufmann WK (1999 ) . Telomere shortening, telomerase
expression, and chromosome instability in rat hepatic epithelial stem-
like cells. Mol Carcinog 24, 209–17.
[43] Wassmann K, and Benezra R (2001 ) . Mitotic checkpoints: from yeast
to cancer. Curr Opin Genet Dev 11, 83–90.
[44] Rudolph KL, Millard M, Bosenberg MW, and DePinho RA (2001 ).
Telomere dysfunction and evolution of intestinal carcinoma in mice and
humans. Nat Genet 28, 155–59.
Neoplasia . Vol. 4, No. 2, 2002
Telomerase and Genomic Stability in CRCC Izumi et al. 111
